Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02455245 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma
A Phase 3 study of Low Grade Glioma, sponsored by Alicia Lenzen.
- Active
- Registry status
- Phase 3
- Development phase
- 95
- Enrollment target
- 20
- Study locations
NCT02455245: Active Phase 3 study of Low Grade Glioma, sponsored by Alicia Lenzen.
NCT02455245 is a Phase 3 study of Low Grade Glioma that is active but no longer recruiting, run by Alicia Lenzen. The registered enrollment target is 95 participants, below the 110-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02455245, a Phase 3 study of Low Grade Glioma, is active but no longer recruiting, sponsored by Alicia Lenzen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 95 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is trying to learn and understand if the chemotherapy drug called carboplatin works as well as the standard therapy. The standard therapy for Low Grade Glioma (LGG) in children and young adults is using a combination of carboplatin and vincristine. Studies in children have shown that the use of carboplatin alone has promise of being just as effective for treating LGG as standard therapy. Additionally, this study will try to understand if treatment with carboplatin alone is associated with an improved quality of life for LGG patients and their families.
Primary Outcome
To compare the progression-free survival (PFS) in patients with previously untreated LGG among patients with and without NF1 utilizing carboplatin/vincristine (standard of care) vs single agent carboplatin (research).
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Carboplatin and Vincristine
Study Locations (20)
Ohio
- Children's Hospital Medical Center of Akron - Akron
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Nationwide Children's Hospital - Columbus
- Dayton Children's Hospital - Dayton
Missouri
- Saint Louis University at SSM Cardinal Glennon Children's Medical Center - St Louis
- Washington University School of Medicine - St Louis
Arizona
- Phoenix Children's Hospital - Phoenix
California
- Rady Children's Hospital - San Diego
Connecticut
- Yale University - New Haven
Florida
- Orlando Health, Inc. - Orlando
Illinois
- Ann & Robert H. Lurie Children's Hosptial of Chicago - Chicago
Indiana
- St. Vincent Peyton Manning Children's Hospital - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2015-03 |
| Est. Completion | 2025-11-30 |
| Phase | Phase 3 |
What the registry record for NCT02455245 still lists
NCT02455245 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 95 participants, a relatively small participant target, below the 110-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (14% lower).
The record links to 1 condition, with Low Grade Glioma appearing as the primary indexed condition, and to 2 interventions - of which Carboplatin is the first listed.
NCT02455245 names 20 study sites across 16 states, led by Ohio, Missouri, Arizona.
Frequently Asked Questions
What is clinical trial NCT02455245 about?
NCT02455245 is a clinical study titled "A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma". This study is trying to learn and understand if the chemotherapy drug called carboplatin works as well as the standard therapy. The standard therapy for Low Grade Glioma (LGG) in children and young adults is using a combination of carboplatin and vincristine. Studies in children have shown that the ...
What is the current status of trial NCT02455245?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 95 participants. The study started on 2015-03. Estimated completion is 2025-11-30.
What conditions does trial NCT02455245 study?
This clinical trial studies the following conditions: Low Grade Glioma.
What interventions are being tested in trial NCT02455245?
The interventions under investigation include: Carboplatin (DRUG), Carboplatin and Vincristine (DRUG).
Who is sponsoring clinical trial NCT02455245?
This trial is sponsored by Alicia Lenzen, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02455245 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02455245's enrollment target sits among peer trials
95 14th of 23 higher than 10 of 23 other Low Grade Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Low Grade Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
RECRUITING · Phase 3
-
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
RECRUITING · Phase 3
-
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
ACTIVE NOT RECRUITING · Phase 3
-
A Vaccine Trial for Low Grade Gliomas
RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia